Le Lézard
Classified in: Covid-19 virus

Global Cancer/Tumor Profiling Market (2021 to 2030) - Opportunity Analysis and Industry Forecasts - ResearchAndMarkets.com


The "Cancer/Tumor Profiling Market by Technique, by Technology and by Application - Global Opportunity Analysis and Industry Forecast 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The Cancer Tumor Profiling Market size was valued at USD 9.32 billion in 2020 and is predicted to reach USD 31.67 billion by 2030 with a CAGR of 12.4% from 2021-2030.

Companies Mentioned

Cancer profiling or the tumor profiling is a laboratory test conducted to identify certain genes or the gene mutations, proteins, or other biomarkers in a sample of tumor tissue. Tumor profiling can aid in treatment planning and predicting if cancer will return or spread to other places of the body. Cancer profiling is not only effective in the molecular profiling of common malignancies like lymphoma and breast cancer, but also in the molecular profiling of lung cancer, prostate cancer, and acute leukaemia. Cancer profiling has become more important in molecular diagnosis, since a better knowledge of cancer tumor allows clinicians to make more informed therapeutic decisions and prevent "over-treating" cancer patients.

Market Dynamics and Trends

Growing prevalence of cancer globally and increasing adoption of precision medicine options are pacing new paths for the advanced diagnostic products for determination of the cancerous gene and targeted therapies for the identical.

According to the International Agency for Research on Cancer, 1 in 5 people develop cancer during their lifetime across globe. Also, 1 in 8 men and 1 in 11 women die from the disease indicating significant need for effective diagnostic and therapeutic options. In addition, increasing new cancer cases owing to ageing population and lifestyle changes are likely to drive the demand for cancer profiling products in the coming years.

Moreover, new estimates from GLOBOCAN suggests that quite 50 million people live within five years of past cancer diagnosis. Factors such as increased research and development activities and new product approvals are expected to enhance the market growth. Furthermore, enormous sums of money are raised for the development of cancer-fighting products.

The high cost of cancer profiling tests, as well as a lack of access to the healthcare infrastructure required for cancer profiling, are limiting the market's expansion over the forecast period. Tumor profiling tests are cutting-edge, and they function by identifying tumor mutations and establishing a therapy pathway tailored to the patient's needs. Due to the exorbitant cost of these tests, which are such a sophisticated technology, they are only used by a small percentage of the population in economically depressed areas. Other factors affecting market growth in the AMEA include a lack of understanding about sophisticated technology, low spending capacity, lack of access to healthcare facilities, and cancer detection at a later stage.

Key Topics Covered:

1. Introduction

2. Cancer Tumor Profiling Market - Executive Summary

3. Market Overview

3.1. Market Definition and Scope

3.2. Market Dynamics

4. Covid-19 Analysis

4.1. Impact of Covid-19 on Cancer or Tumor Profiling Market

5. Market Share Analysis

5.1. Market Share Analysis of Top Global Cancer Tumor Profiling Providers, 2020

5.2. Market Share Analysis of Top Amea Cancer Tumor Profiling Providers, 2020

5.3. Market Share Analysis of Top Amea Cancer Tumor Profiling Providers, 2020

5.4. Market Share Analysis of Top North America Cancer Tumor Profiling Providers, 2020

5.5. Market Share Analysis of Top Europe Cancer Tumor Profiling Providers, 2020

5.6. Market Share Analysis of Top APAC Cancer Tumor Profiling Providers, 2020

5.7. Market Share Analysis of Top Row Cancer Tumor Profiling Providers, 2020

6. Premium Insights

6.1. Prevalence of Cancer by Key Countries

6.2. Overview of Cgp Technology Vs Hotspot Technology

6.3. Comprehensive Genome Profiling:

6.4. Cancer Hot Spot Testing

6.5. Uptake of Cgp Vs Hotspot Technique in Amea Region

6.6. Existing and Emerging Technologies of Cancer/Tumor Profiling

6.7. Genotyping

6.8. Next Generation Sequencing

6.9. Emerging Technologies for Cancer Profiling

7. Global Cancer Tumor Profiling Market, by Technique

7.1. Overview

7.2. Genomic

7.3. Proteomic

7.4. Metabolomics

7.5. Epigenetics

8. Global Cancer Tumor Profiling Market, by Technology

8.1. Overview

8.2. Immunoassay

8.3. Ngs

8.4. Insitu Hybridization

8.5. Mass Spectrometry

8.6. Pcr

8.7. Microarray

8.8. Others

9. Global Cancer Tumor Profiling Market, by Application

9.1. Overview

9.2. Research Application

9.3. Clinical Application

10. Global Cancer Tumor Profiling Market, by Region

10.1. Overview

10.2. North America

10.3. Europe

10.4. Asia-Pacific

10.5. Latin America

10.6. Middle East

10.7. Africa

11. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/kyy5za


These press releases may also interest you

at 21:00
SETC-Assistance.org Helps Eligible Self-Employed Workers Receive Up to $32,220 in Tax Credits Through SETC Program
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

at 19:30
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDEL
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

at 19:05
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:51
Bladex announces 1Q24 Net Profit of $51.3 Million, or $1.40 per share, expanding its annualized return on equity to 16.8% in 1Q24
Banco Latinoamericano de Comercio Exterior, S.A. , a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced...

at 17:20
NOVAGOLD Releases 2023 Sustainability Report
Providing a comprehensive overview of NOVAGOLD's Environmental, Social and Governance (ESG) performance, emphasizing remarkable health and safety records, steadfast dedication to environmental protection, continuous community investment, extensive...

at 16:45
Dogness Reports Financial Results for the Six Months Ended December 31, 2023
Dogness (International) Corporation ("Dogness" or the "Company") , a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced its financial results for the six months ended December...

More news about Covid-19 virus...


News published on and distributed by: